- Home
- CGTX vs BRNS Comparison
CGTX vs BRNS Comparison
Compare CGTX & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGTX
- BRNS
- Stock Information
- Founded
- CGTX 2007
- BRNS 2016
- Country
- CGTX United States
- BRNS United Kingdom
- Employees
- CGTX N/A
- BRNS N/A
- Industry
- CGTX Biotechnology: Pharmaceutical Preparations
- BRNS Biotechnology: Pharmaceutical Preparations
- Sector
- CGTX Health Care
- BRNS Health Care
- Exchange
- CGTX Nasdaq
- BRNS Nasdaq
- Market Cap
- CGTX 53.4M
- BRNS 48.3M
- IPO Year
- CGTX 2021
- BRNS 2021
- Fundamental
- Price
- CGTX $1.61
- BRNS $1.05
- Analyst Decision
- CGTX Strong Buy
- BRNS Strong Buy
- Analyst Count
- CGTX 3
- BRNS 1
- Target Price
- CGTX $2.83
- BRNS $3.00
- AVG Volume (30 Days)
- CGTX 8.1M
- BRNS 41.2K
- Earning Date
- CGTX 11-12-2025
- BRNS 11-05-2025
- Dividend Yield
- CGTX N/A
- BRNS N/A
- EPS Growth
- CGTX N/A
- BRNS N/A
- EPS
- CGTX N/A
- BRNS N/A
- Revenue
- CGTX N/A
- BRNS $14,969,000.00
- Revenue This Year
- CGTX N/A
- BRNS N/A
- Revenue Next Year
- CGTX N/A
- BRNS N/A
- P/E Ratio
- CGTX N/A
- BRNS N/A
- Revenue Growth
- CGTX N/A
- BRNS 1766.46
- 52 Week Low
- CGTX $0.22
- BRNS $0.64
- 52 Week High
- CGTX $3.83
- BRNS $2.92
- Technical
- Relative Strength Index (RSI)
- CGTX 42.22
- BRNS 40.11
- Support Level
- CGTX $1.43
- BRNS $1.08
- Resistance Level
- CGTX $2.60
- BRNS $1.20
- Average True Range (ATR)
- CGTX 0.32
- BRNS 0.09
- MACD
- CGTX -0.17
- BRNS -0.01
- Stochastic Oscillator
- CGTX 10.81
- BRNS 3.23
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.